Article Details

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from Oppenheimer

Retrieved on: 2019-04-03 13:14:16

Tags for this article:

Click the tags to see associated articles and topics

Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from Oppenheimer. View article details on HISWAI:

Excerpt

<div><b>WINTON GROUP</b> Ltd acquired a new stake in Urogen Pharma in the 3rd quarter valued at approximately $221,000. Finally, JPMorgan Chase & Co.</div>

Article found on:

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up